Geneos Wealth Management Inc. Arrowhead Pharmaceuticals, Inc. Transaction History

Geneos Wealth Management Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$58.38 - $84.96 $215,655 - $313,842	-3,694 Closed	0 $0
Q2 2021 Jul 08, 2021	SELL	$62.15 - $90.32 $279,675 - $406,439	-4,500 Reduced 54.92%	3,694 $233,000
Q1 2021 Jun 17, 2021	BUY	$61.35 - $90.47 $276,075 - $407,115	4,500 Added 121.82%	8,194 $596,000
Q4 2020 May 19, 2021	BUY	$43.82 - $85.37 $161,871 - $315,356	3,694 New	3,694 $232,000
Q1 2020 Sep 07, 2021	SELL	$20.56 - $63.12 $62,152 - $190,811	-3,023 Closed	0 $0

Q4 2019 Sep 07, 2021	SELL	$28.14 - $73.01 $17,193 - $44,609	-611 Reduced 16.81%	3,023 $196,000
Q3 2019 Sep 07, 2021	BUY	$26.26 - $34.86 $47,215 - $62,678	1,798 Added 97.93%	3,634 $97,000
Q2 2019 Sep 07, 2021	BUY	$17.43 - $28.82 $32,001 - $52,913	1,836 New	1,836 $48,000
Q1 2019 Sep 07, 2021	SELL	$12.05 - $20.18 $31,125 - $52,124	-2,583 Closed	0 $0
Q3 2018 Sep 07, 2021	BUY	$14.0 - $20.3 $36,162 - $52,434	2,583 New	2,583 $49,000
Q1 2017 Sep 07, 2021	SELL	N/A	-8,002 Closed	0 $0
Q4 2016 Sep 07, 2021	BUY	N/A	8,002	8,002 $12,000

296

88.5M

905K

387K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.71B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

Stay updated on Geneos Wealth Management Inc. with notifications on news.